[go: up one dir, main page]

MX2016013189A - Formulaciones solidas que contienen omega-3 y resveratrol. - Google Patents

Formulaciones solidas que contienen omega-3 y resveratrol.

Info

Publication number
MX2016013189A
MX2016013189A MX2016013189A MX2016013189A MX2016013189A MX 2016013189 A MX2016013189 A MX 2016013189A MX 2016013189 A MX2016013189 A MX 2016013189A MX 2016013189 A MX2016013189 A MX 2016013189A MX 2016013189 A MX2016013189 A MX 2016013189A
Authority
MX
Mexico
Prior art keywords
omega
resveratrol
formulations containing
solid formulations
containing omega
Prior art date
Application number
MX2016013189A
Other languages
English (en)
Other versions
MX369782B (es
Inventor
Giannini Giuseppe
SANTANIELLO Mosé
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of MX2016013189A publication Critical patent/MX2016013189A/es
Publication of MX369782B publication Critical patent/MX369782B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)

Abstract

La presente solicitud se refiere en la invención una composición sólida que comprende ácidos grasos poliinsaturados omega-3 (n-3 PUFA), o sus esteres de alquilo o resveratrol, adsorbidos en un sustrato inerte y en donde la recuperación de omega-3 es al menos 96 % después de 6 meses a 25oC. La composición de acuerdo a la presente invención se puede formular como complemento alimenticio o medicamento para prevenir o tratar enfermedades cardiovasculares debidas a trastornos en el metabolismo de los lípidos y a la agregación incrementada de plaquetas; a daños debidos a radicales libres, seleccionados del grupo que consiste de arterosclerosis, cáncer, enfermedad inflamatoria de articulaciones, asmas, diabetes, demencia senil y enfermedad ocular degenerativa; y/o enfermedades virales.
MX2016013189A 2014-06-04 2015-03-26 Formulaciones solidas que contienen omega-3 y resveratrol. MX369782B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14001940.7A EP2952180B1 (en) 2014-06-04 2014-06-04 Solid formulations containing resveratrol and omega-3 polyunsaturated fatty acids (n-3 PUFA)
PCT/EP2015/056530 WO2015185239A1 (en) 2014-06-04 2015-03-26 Solid formulations containing omega-3 and resveratrol

Publications (2)

Publication Number Publication Date
MX2016013189A true MX2016013189A (es) 2017-01-16
MX369782B MX369782B (es) 2019-11-21

Family

ID=50884650

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013189A MX369782B (es) 2014-06-04 2015-03-26 Formulaciones solidas que contienen omega-3 y resveratrol.

Country Status (14)

Country Link
US (1) US20170112791A1 (es)
EP (1) EP2952180B1 (es)
JP (1) JP2017522278A (es)
CN (1) CN106456587B (es)
AU (1) AU2015271278A1 (es)
CA (1) CA2943021A1 (es)
EA (1) EA032762B1 (es)
ES (1) ES2615630T3 (es)
MX (1) MX369782B (es)
PL (1) PL2952180T3 (es)
PT (1) PT2952180T (es)
SI (1) SI2952180T1 (es)
UA (1) UA119174C2 (es)
WO (1) WO2015185239A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060004646A (ko) * 2002-08-14 2006-01-12 이 아이 듀폰 디 네모아 앤드 캄파니 고 액체 부하량을 가진 유동성 고상 분말
ITRM20020562A1 (it) 2002-11-06 2004-05-07 Sigma Tau Ind Farmaceuti Uso del resveratrolo per la preparazione di un medicamento utile per il trattamento delle infezioni da virus dell'influenza.
WO2009034124A1 (en) * 2007-09-12 2009-03-19 Novozymes A/S Omega-3 stabilisation towards oxidation
KR101100078B1 (ko) * 2008-03-27 2011-12-29 홉킨스바이오연구센터(주) 관절염 치료를 위한 약제학적 조성물
CN102413813B (zh) * 2009-03-24 2014-11-12 Adds制药有限责任公司 用于口服递送的稳定化的溶解性增强的制剂
BR112012015500A2 (pt) 2009-12-23 2016-05-03 Defiante Farmaceutica Sa composição de combinação útil para o tratamento de doenças cardiovasculares
US20110244031A1 (en) * 2010-03-31 2011-10-06 Lifecycle Pharma A/S Porous tablets as carriers for liquid formulations
IT1400695B1 (it) 2010-06-21 2013-06-28 Labomar S R L Composizioni farmaceutiche e/o nutraceutiche contenenti principi attivi insolubili in acqua e procedimento per ottenerle.
US9770508B2 (en) * 2012-09-12 2017-09-26 Novaliq Gmbh Semifluorinated alkane compositions

Also Published As

Publication number Publication date
EA201692399A1 (ru) 2017-03-31
MX369782B (es) 2019-11-21
PT2952180T (pt) 2017-03-02
CN106456587B (zh) 2020-03-20
AU2015271278A1 (en) 2016-11-10
EP2952180A1 (en) 2015-12-09
CN106456587A (zh) 2017-02-22
EA032762B1 (ru) 2019-07-31
JP2017522278A (ja) 2017-08-10
UA119174C2 (uk) 2019-05-10
US20170112791A1 (en) 2017-04-27
CA2943021A1 (en) 2015-12-10
ES2615630T3 (es) 2017-06-07
EP2952180B1 (en) 2017-01-25
PL2952180T3 (pl) 2017-05-31
SI2952180T1 (sl) 2017-05-31
WO2015185239A1 (en) 2015-12-10

Similar Documents

Publication Publication Date Title
PE20170253A1 (es) Lipido que comprende acidos grasos poliinsaturados de cadena larga
MX349678B (es) Producción de ácidos grasos poliinsaturados de cadena larga en células vegetales.
MX2018003636A (es) Composicion de uridina y citidina para su uso en la prevencion o tratamiento de neurotrauma.
HK1206248A1 (en) Compositions of statins and omega-3 fatty acids
MX372724B (es) Formulaciones de acido eicosapentaenoico (epa).
MX356427B (es) Emulsion que contiene hormona.
PH12014500105A1 (en) Fatty acid compositions
GEP201606568B (en) Compositions for the treatment of neurologic disorders
JP2016512245A5 (ja) マイボーム腺を標的とする組成物
WO2016040570A3 (en) Dietary emulsion formulations and methods for using the same
BR112014013593A8 (pt) retenção de dha durante o processamento de óleo de canola
BR112018001164A2 (pt) composto de fórmula geral, composição farmacêutica e método para o tratamento de uma doença cardiovascular
BR112017013445A2 (pt) processo para aumentar a estabilidade de uma composição que compreende ácidos graxos ômega 6 poli-insaturados
EA201591680A1 (ru) Смесь жирных кислот (гжк, группа жирных кислот) и её применение для лечения воспалительных патологий
WO2014165190A3 (en) Compositions comprising docosapentaenoic acid and methods of use
CO2017001088A2 (es) Mezcla de ácidos grasos y palmitoiletanolamida para su uso en el tratamiento de patologías inflamatorias y alérgicas
UA111967C2 (uk) Оздоровчий харчовий продукт, що містить етилові естери жирних кислот з лляної олії, і спосіб його одержання
MX2015007085A (es) Composiciones de acido omega-3 pentanoico y metodos de uso.
PL3784044T3 (pl) Kompozycje wielonienasyconych kwasów tłuszczowych wzbogacone w dha
CO2017005911A2 (es) Método para incrementar niveles de ácidos grasos de omega-3 en productos de carne de res por medio de administración de una dieta de pasto y algas
PL3809858T3 (pl) Kompozycje wielonienasyconych kwasów tłuszczowych wzbogacone w dha
MX2016013189A (es) Formulaciones solidas que contienen omega-3 y resveratrol.
MX2022005627A (es) Lipido que comprende acido docosapentaenoico.
PH12017500738A1 (en) Feeding algae to cattle at low doses to produce high omega 3 levels in beef
MX361765B (es) Formulacion homogenea que comprende acido graso poliinsaturado omega-3 y resveratrol para administracion oral.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ALFASIGMA S.P.A.

FG Grant or registration